An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC-Reference-Cited by-同舟云学术

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC

Published:2020-09 Issue:9 Volume:15 Page:1484-1496
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Zhu Viola W.,Lin Yen-Ting,Kim Dong-Wan,Loong Herbert H.,Nagasaka Misako,To Hao,Ang Yvonne Li-En,Ock Chan-Young,Tchekmedyian Nishan,Ou Sai-Hong Ignatius,Syn Nicholas L.,Reungwetwattana Thanyanan,Lin Chia-Chi,Soo Ross A.

Funder

Merck

Novartis

AstraZeneca

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance;Schram;Nat Rev Clin Oncol,2017

2. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

3. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study;Solomon;Lancet Oncol,2018